| P2093 | author name string | Paramita M Ghosh | |
| | Zsofia Kiss | |
| P2860 | cites work | RIGUI, a putative mammalian ortholog of the Drosophila period gene | Q24316037 |
| | Putative human blue-light photoreceptors hCRY1 and hCRY2 are flavoproteins | Q24318911 |
| | Glucocorticoid regulation of the circadian clock modulates glucose homeostasis | Q24657351 |
| | Coordination of circadian timing in mammals | Q27860673 |
| | Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. | Q27863659 |
| | Circadian oscillation of a mammalian homologue of the Drosophila period gene | Q27867702 |
| | Molecular components of the mammalian circadian clock | Q28264527 |
| | Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study | Q28383609 |
| | Molecular analysis of mammalian circadian rhythms | Q29618036 |
| | Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study | Q30497028 |
| | Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression | Q31912900 |
| | Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity | Q33396400 |
| | Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. | Q33498754 |
| | The circadian clock protein BMAL1 is necessary for fertility and proper testosterone production in mice | Q33821636 |
| | Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms | Q34058703 |
| | Prospective study of sex hormone levels and risk of prostate cancer | Q34392447 |
| | Molecular tools to study melatonin pathways and actions. | Q34430531 |
| | Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. | Q34545999 |
| | Melatonin deficiencies in women | Q34602923 |
| | Circadian chemotherapy for gynecological and genitourinary cancers | Q34606499 |
| | Upregulation of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells | Q34784899 |
| | Circadian clock genes and risk of fatal prostate cancer | Q34810303 |
| | The circadian clock: pacemaker and tumour suppressor | Q35118733 |
| | Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells | Q35172397 |
| | Gonadectomy reveals sex differences in circadian rhythms and suprachiasmatic nucleus androgen receptors in mice | Q35694499 |
| | Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. | Q35947279 |
| | Does night-shift work increase the risk of prostate cancer? a systematic review and meta-analysis | Q36142304 |
| | Sleep interruption associated with house staff work schedules alters circadian gene expression | Q36209437 |
| | Does "clock" matter in prostate cancer? | Q36629390 |
| | A role for the clock gene per1 in prostate cancer | Q37373255 |
| | Clinical uses of melatonin: evaluation of human trials | Q37737750 |
| | Melatonin's role in preventing toxin-related and sepsis-mediated hepatic damage: A review. | Q38710738 |
| | A review of the protective effect of melatonin in pesticide-induced toxicity | Q38902267 |
| | Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevent | Q39303608 |
| | Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. | Q39538005 |
| | Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells | Q39578109 |
| | Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy | Q39744296 |
| | Molecular mechanisms of melatonin anticancer effects | Q39755885 |
| | Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. | Q39833800 |
| | Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer | Q39838789 |
| | Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. | Q39959693 |
| | Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro | Q39995755 |
| | Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention | Q40173621 |
| | Role of protein kinase Calpha in melatonin signal transduction | Q40280478 |
| | Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism | Q40513840 |
| | Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models | Q40675796 |
| | Nuclear exclusion of the androgen receptor by melatonin | Q40717180 |
| | Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity | Q40777339 |
| | Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. | Q40848746 |
| | Hormonal interactions in human prostate tumor LNCaP cells | Q40958828 |
| | Cancer incidence among 10,211 airline pilots: a Nordic study. | Q42444677 |
| | Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin | Q42516482 |
| | Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis | Q43284403 |
| | Inhibition of Dunning tumor growth by melatonin | Q43531475 |
| | Age-related changes in plasma dehydroepiandrosterone sulphate, cortisol, testosterone and free testosterone circadian rhythms in adult men. | Q43638776 |
| | Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. | Q43999235 |
| | Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity | Q44059675 |
| | Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. | Q44461583 |
| | Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype | Q44558492 |
| | Circadian rhythm of the Leydig cells endocrine function is attenuated during aging. | Q46642424 |
| | Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. | Q46844720 |
| | Cellular construction of a circadian clock: period determination in the suprachiasmatic nuclei | Q48575076 |
| | Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones | Q48587194 |
| | Effect of Transtympanic Injection of Melatonin on Cisplatin-Induced Ototoxicity. | Q48878710 |
| | The noncircadian function of the circadian Clock gene in the regulation of male fertility. | Q50938059 |
| | Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma. | Q52428594 |
| | Increased and mistimed sex hormone production in night shift workers. | Q52657864 |
| | Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. | Q53656340 |
| | Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis | Q59489053 |
| | Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling | Q60467122 |
| | Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells | Q60714531 |
| | Hormonally induced tumors of the reproductive system of parabiosed male rats | Q66921912 |
| | Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor | Q68416543 |
| | Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma | Q68426239 |
| | Circadian timing of cancer chemotherapy | Q69884877 |
| | Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk | Q70856785 |
| | Loss of circadian rhythmicity in blood testosterone levels with aging in normal men | Q71709444 |
| | Circadian variation in serum free and non-SHBG-bound testosterone in normal men: measurements, and simulation using a mass action model | Q72920659 |
| | Antiproliferative action of melatonin on human prostate cancer LNCaP cells | Q73442041 |
| | Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy | Q73685231 |
| | Antiproliferative effects of melatonin and CGP 52608 | Q74620899 |
| | Melatonin receptors in PC3 human prostate tumor cells | Q77788314 |
| | Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer | Q77848976 |
| | An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone | Q81469973 |
| | Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment | Q83094556 |
| | Melatonin and beta-glucan alone or in combination inhibit the growth of dunning prostatic adenocarcinoma | Q84581037 |
| | Contribution of testosterone to the clock system in rat prostate mesenchyme cells | Q86932398 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circadian rhythm | Q208353 |
| | prostate cancer | Q181257 |
| P304 | page(s) | T123-T134 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Endocrine-Related Cancer | Q3054004 |
| P1476 | title | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer | |
| P478 | volume | 23 | |